Compared with the M and EcN groups, EcN‐GLP‐1, and exenatide treatments significantly reversed those changes, suggesting that supplementation of GLP‐1 through engineered EcN‐GLP‐1 strain or its analog might protect the degeneration of dopaminergic neurons by modulating the content of major protein involved in PD‐associated multiple cellular pathways. This evidence concerns the gene GLP1R and Parkinson disease.